Pharmaceutical Industry in
Allschwil
51 companies in Pharmaceutical Industry based in Allschwil — name and year of registration from the commercial register.
50 of 51 companies
Abbott Products Operations AG
Since 2000 · 21–50 empl.5.0(5)
Abbott Products Operations AG is a healthcare company that develops, manufactures and supplies products and therapies in diabetes management, diagnostics, medical nutrition, vascular therapies and neuromodulation. The website specifically lists diabetes-care solutions such as the FreeStyle Libre blood glucose monitoring system.
Basilea Pharmaceutica International AG, Allschwil
Since 2008 · 101–500 empl.4.5(2)
Basilea Pharmaceutica International AG, Allschwil develops and commercializes pharmaceutical products focused on anti-infectives, particularly antifungal and antibiotic therapies. The company’s portfolio includes Cresemba (isavuconazole) and Zevtera (ceftobiprole), and it maintains clinical and preclinical programs for additional anti-infective candidates.
Idorsia Pharmaceuticals Ltd
Since 2017 · 500+ empl.3.9(19)
Idorsia Pharmaceuticals Ltd discovers, develops and commercializes medicines. The company maintains a diversified clinical pipeline including CNS, cardiovascular, immunological and orphan disease programmes and manages research, clinical development, regulatory registration, production and quality activities.
Basilea Pharmaceutica AG, Allschwil
Since 2002 · 101–500 empl.4.5(2)
Basilea Pharmaceutica AG, Allschwil is a pharmaceutical company that develops and commercializes medicines for severe and life‑threatening bacterial and fungal infections. Its portfolio includes antifungal and antibacterial products such as Cresemba (isavuconazole) and Zevtera.
Merz Pharma (Schweiz) AG
Since 1977 · 51–100 empl.
The core activity of Merz Therapeutics is the development, manufacture and marketing of pharmaceuticals, particularly in the fields of neurology, hepatology and dermatology. The company focuses on researching and developing innovative therapies to improve the quality of life for patients.
Pharmatrans Sanaq AG
Since 1982 · 11–20 empl.
The core activity of Pharmatrans SANAQ AG is the development, manufacture and distribution of excipients and active ingredients for the pharmaceutical industry. The company offers standardized and customer-specific solutions and supports its customers in the development and production of medicinal products.
Andreabal AG
Since 1988 · 11–20 empl.
The core activity of Andreabal AG is the development, manufacture and distribution of products for women before, during and after pregnancy, including pregnancy preparation, breastfeeding and menopause, as well as vitamins, iron deficiency and skin and nail care products.
Abbott Laboratories GmbH
Since 1989 · 51–100 empl.
Abbott Laboratories GmbH develops and supplies healthcare products and solutions, with a focus on diagnostics, diabetes-care systems, cardiovascular (heart and vascular) therapies and medical nutrition.
Actelion Pharmaceuticals Ltd
Since 1997 · 21–50 empl.
Actelion Pharmaceuticals Ltd is a pharmaceutical company focused on the research, development, and marketing of medicines. The website presents Johnson & Johnson Innovative Medicine’s therapeutic areas, including oncology, immunology, neuroscience, and cardiopulmonary care.
Xenometrix AG
Since 2005 · 1–10 empl.
Xenometrix AG supplies bioassay products and related analytical services for mutagenicity, genotoxicity, endocrine activity screening and skin absorption studies. The company produces and distributes standardized test kits (including miniaturized Ames test formats such as Ames II and Ames MPF), XenoScreen endocrine receptor assays, micronucleus and cytotoxicity assays, and offers GLP and non‑GLP service analytics as well as kit components and ex‑vivo skin samples for penetration testing.
T3 Pharmaceuticals AG
Since 2015 · 11–20 empl.
The core activity of T3 Pharmaceuticals AG is the development of anti-cancer drugs, particularly through the research and development of innovative therapeutics based on microbial pathogenesis and immunotherapy. The company focuses on the discovery and development of new active substances (NCEs) and the clinical development of targeted therapeutics, especially in the fields of oncology and hematology.
acovos AG
Since 2017 · 1–10 empl.
The core activity of Acovos is to provide high-quality, well-characterized human tissue samples for the pharmaceutical and biotechnology industries. In particular, Acovos offers a comprehensive collection of formalin-fixed, paraffin-embedded (FFPE) tissue samples, including tumor, inflammatory, degenerative and normal tissues, as well as matching tissue pairs and tissue samples tested for specific antibodies. These samples are used for the development of drugs and diagnostic products.
CAPTOR THERAPEUTICS GmbH
Since 2018 · 11–20 empl.
The core activity of Captor Therapeutics is the development of medicines, particularly in the early stages of drug development, with a focus on reprogramming proteins to treat previously incurable diseases.
Alloy Therapeutics (Switzerland) AG
Since 2019 · 21–50 empl.
Alloy Therapeutics (Switzerland) AG develops and provides technologies and services for drug discovery and development. Its activities focus on antibodies and multispecifics, TCR mimics, genetic medicines, pharmacology, and AI/ML-enabled platforms.
AlphaMol Science AG
Since 2019 · 1–10 empl.
AlphaMol Science AG develops and applies integrated approaches combining computational biology, biochemistry, medicinal chemistry, pharmacology and biotechnology to support small-molecule drug discovery and design. The company’s activities include GPCR molecular research, in vitro biotesting, membrane protein structure studies and development of computational algorithms for drug discovery.
Neurocrine Switzerland GmbH
Since 2023 · 1–10 empl.
Neurocrine Switzerland GmbH conducts research and development of treatments for neurological, neuroendocrine and neuropsychiatric disorders. The organisation’s portfolio includes approved medicines for conditions such as tardive dyskinesia, chorea associated with Huntington’s disease, congenital adrenal hyperplasia, endometriosis and uterine fibroids, and it maintains a pipeline with compounds in mid‑to‑late stage clinical development.
InCephalo AG
Since 2021 · 1–10 empl.
The core activity of InCephalo Therapeutics is the development and research of local therapies for neurological diseases, particularly brain cancer. The company focuses on the development of biological drugs specifically designed for local application in the central nervous system (CNS) to minimize side effects and maximize efficacy. The proprietary Compartment Lock technology (C-Lock) enables the local retention of biological drugs in the CNS, prolonging their effect while minimizing systemic exposure.
Blue Wave Therapeutics GmbH
Since 2021 · 11–20 empl.
The core activity of Blue Wave Therapeutics GmbH is the development of targeted radionuclide therapies for the treatment of solid tumors.
Bright Peak Therapeutics AG
Since 2017 · 51–100 empl.5.0(1)
The core activity of Bright Peak Therapeutics is the development of cancer medications, particularly in the field of immuno-oncology, antibody-drug conjugates (ADCs) and biologics.
Merz Aesthetics (Schweiz) AG
Since 2023 · 1–10 empl.4.4(7)
Merz Aesthetics (Schweiz) AG develops and markets medicinal products and patient-focused services in therapeutic areas such as neurology, dermatology and health. Its activities include therapies and supporting services for patients.
Alentis Therapeutics AG
Since 2019 · 21–50 empl.5.0(1)
The core activity of Alentis Therapeutics AG is the development and research of medicines, particularly in the field of fibrosis and cancer treatment with antibody-drug conjugates (ADCs). The company focuses on developing innovative therapies that directly target the cause of the disease and can prevent or reverse the progression of diseases such as fibrosis and cancer.
MiHKAL GmbH
Since 2021 · 1–10 empl.
The core activity of MiHKAL GmbH is the research and development of new medicines, particularly antidepressants, through the synthesis and development of small molecules and psychoactive compounds.
Palto Therapeutics AG
Since 2020 · 1–10 empl.
Palto Therapeutics AG develops novel formulations for biological drugs, focusing on oligonucleotide-based therapeutics such as siRNAs to enable targeted cellular uptake and cytoplasmic activation. The company designs proprietary formulation and delivery strategies to address in vivo stability and achieve tissue- or cell-type-specific distribution.
Phialogics AG
Since 2022 · 1–10 empl.
Preclina Europe GmbH
Since 2024 · 1–10 empl.
Preclina Europe GmbH is a non-clinical CRO providing an integrated drug-discovery platform focused on immunology and inflammatory disorders. Services listed on the website include cell-based assays using patient-derived cells, histopathology services, and PK/ADME/toxicology testing.
Nanolynx Biologics AG
Since 2025 · 1–10 empl.
Nanolynx Biologics AG develops conditionally active nanobody-drug conjugates (CA-NDCs) for hard-to-treat solid tumors. The company uses an AI-enabled discovery platform and focuses on tumor-selective biologics for oncology targets such as CD70, CD142 and Nectin-4.
Ilonov Therapeutics SA
Since 2025 · 1–10 empl.
Ilonov Therapeutics SA is a preclinical-stage biopharmaceutical company developing first-in-class biotherapies for diabetes and metabolic diseases by leveraging the muscle secretome and myokines; its lead program centers on the myokine candidate ILV-001, which aims to protect pancreatic islets and support therapies for type 1 and type 2 diabetes.
Gubra GmbH
Since 2026 · 1–10 empl.
Gubra GmbH is a biotechnology company operating through Biotech, CRO services and Ventures. It develops peptide-based drug candidates and provides preclinical research and development services across areas such as obesity, liver, kidney, lung and metabolic diseases.
Hemastatx GmbH
Since 2025 · 1–10 empl.
Hemastatx GmbH develops targeted therapies for severe bleeding disorders and is advancing HMX-001, a monoclonal antibody program for von Willebrand factor (VWF)–related bleeding disorders. HMX-001 is designed to inhibit ADAMTS13 activity to preserve functional high‑molecular‑weight VWF multimers and help control bleeding episodes.
GlioCART GmbH
Since 2025 · 1–10 empl.
GlioCART GmbH develops a dual-action CAR-T therapy for glioblastoma. The company focuses on directly attacking tumor cells while also reprogramming the immunosuppressive tumor microenvironment.
Cancentus GmbH
Since 2026 · 1–10 empl.
Aschem GmbH
Since 2018 · 1–10 empl.
The core activity of ASCHEM GmbH is the development, synthesis and marketing of various chemical building blocks for drug development and production, as well as the provision of services in the field of nanotechnology, including the development of nano-based drug formulations and targeted drug delivery systems.
Immuna Therapeutics AG
Since 2025 · 1–10 empl.
Immuna Therapeutics AG develops cell and gene therapies, with a focus on CAR-T and gene therapy platforms for blood cancers and other indications. The company supports hospitals and health systems with decentralized GMP manufacturing, regulatory support, and commercialization.
BIIE AI Initiative AG
Since 2025 · 1–10 empl.
BIIE AI Initiative AG is the AI initiative of the Botnar Institute of Immune Engineering (BIIE). The website mainly provides privacy policy information and a contact/newsletter form; it contains little detail about specific products or services.
PharmaBiome AG
Since 2020 · 1–10 empl.
Elaaj Bio AG
Since 2021 · 1–10 empl.
Engimmune Therapeutics AG
Since 2021 · 1–10 empl.
Onena Medicines AG
Since 2022 · 1–10 empl.
Glycocalyx Therapeutics AG
Since 2022 · 1–10 empl.
BioNexus GmbH
Since 2023 · 1–10 empl.
Treeline Biosciences GmbH
Since 2023 · 1–10 empl.
Epicelya Therapeutics AG
Since 2024 · 1–10 empl.
Viatris Innovation GmbH
Since 2024 · 1–10 empl.
Soivera GmbH
Since 2024 · 1–10 empl.
NAHLER Regulatory Affairs Consulting
Since 2024 · 1–10 empl.
Fy Cappa Biologics AG
Since 2024 · 1–10 empl.
Maeven AG
Since 2025 · 1–10 empl.
Sironax Switzerland GmbH
Since 2025 · 1–10 empl.
NBTX GmbH
Since 2025 · 1–10 empl.
Alsyslife AG
Since 2025 · 1–10 empl.
Pharmaceutical Industry in Allschwil
Pharmaceutical Industry in the region
Point size by number of companies per place.
Source: commercial register (Zefix) · as of October 10, 2026
Pharmaceutical Industry in other places
By canton